Can Gilead make remdesivir pay?
Gilead has been rewarded handsomely, via share price gains, for its Covid-19 remdesivir work, but the potential costs should not be forgotten.
Long term forecasts confirm Keytruda’s dominance
Keytruda sales could be more than double any other product in 2026, new estimates suggests, as Merck’s cancer drug surges into the record books.
Covid-19 adds a new danger to drug launches
Launch phase is a challenging time for drug developers, so consider the likes of Biohaven, Esperion and, most recently, Urogen, as they brave locked-down markets.
New Covid-19 test and a decent first quarter buoy Abbott
Diagnostics prove defensive for Abbott, as the company jumps the FDA’s gun with its third coronavirus test.
